MedTrace Logo

Effects of EMDR on Psychological Symptoms and EEG Findings in Trauma-Exposed Individuals

NCT07206381 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-30

No results posted yet for this study

Summary

This study will examine the effects of Eye Movement Desensitization and Reprocessing (EMDR) group therapy on adults who experienced the April 2025 Silivri earthquake in Turkey. Participants will be randomly assigned to either an EMDR intervention group or a waitlist control group. Psychological symptoms will be measured using the PTSD Checklist for DSM-5 (PCL-5), the Depression, Anxiety, and Stress Scale (DASS-21), the Short Form Health Survey (SF-36), and the Pittsburgh Sleep Quality Index (PSQI). Quantitative EEG (QEEG) recordings will also be collected before and after the intervention to assess changes in brain activity related to emotional regulation and trauma processing. The goal of the study is to evaluate whether EMDR produces both clinical and neurophysiological improvements in trauma-exposed individuals.

Conditions

  • PTSD - Post Traumatic Stress Disorder
  • Depression
  • Anxiety Disorders and Symptoms
  • Sleep Quality
  • Quality of Life

Interventions

BEHAVIORAL

Eye Movement Desensitization and Reprocessing (EMDR) Group Therapy

Sessions conducted in groups with one therapist and one co-therapist; each session follows the EMDR standard protocol.

Sponsors & Collaborators

  • Istanbul Galata University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-04
Primary Completion
2026-05-30
Completion
2026-08-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07206381 on ClinicalTrials.gov